xl184 Does cabozantinib enter the brain?

XL184 (i.e., cabozantinib) has shown potential in some clinical studies to cross the blood-brain barrier and enter brain tissue. Although it is able to penetrate the blood-brain barrier, its effectiveness in treating brain metastases is still under investigation. The treatment of brain metastases faces many challenges, including whether the drug can effectively cross the blood-brain barrier, whether the drug is adequately distributed in the brain, and whether other adverse effects will occur. Therefore, for patients with brain metastases, the use of XL184 requires close monitoring and the development of individualized treatment plans based on specific circumstances to ensure the best therapeutic effect and safety.